Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy

Dolcino, Marzia; Tinazzi, Elisa; Pelosi, Andrea; Patuzzo, Giuseppe; Moretta, Francesca; Lunardi, Claudio; Puccetti, Antonio

doi:10.3390/genes8040127

Cited by 14 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differentially expressed genes (DEGs) in PsA samples from our previous study [ 8 ] were mapped onto the STRING database [ 16 ] to detect protein-protein interactions (PPI) pairs validated by experimental studies. Network and modular analysis were carried out as we previously described [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

MicroRNA Expression Profiling in Psoriatic Arthritis

Pelosi

Lunardi

Fiore

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by bone erosions and new bone formation. MicroRNAs (miRNAs) are key regulators of the immune responses. Differential expression of miRNAs has been reported in several inflammatory autoimmune diseases; however, their role in PsA is not fully elucidated. We aimed to identify miRNA expression signatures associated with PsA and to investigate their potential implication in the disease pathogenesis. Methods miRNA microarray was performed in blood cells of PsA patients and healthy controls. miRNA pathway analyses were performed and the global miRNA profiling was combined with transcriptome data in PsA. Deregulation of selected miRNAs was validated by real-time PCR. Results We identified specific miRNA signatures associated with PsA patients with active disease. These miRNAs target pathways relevant in PsA, such as TNF, MAPK, and WNT signaling cascades. Network analysis revealed several miRNAs regulating highly connected genes within the PsA transcriptome. miR-126-3p was the most downregulated miRNA in active patients. Noteworthy, miR-126 overexpression induced a decreased expression of genes implicated in PsA. Conclusions This study sheds light on some epigenetic aspects of PsA identifying specific miRNAs, which may represent promising candidates as biomarkers and/or for the design of novel therapeutic strategies in PsA.

show abstract

Section: Methodsmentioning

confidence: 99%

MicroRNA Expression Profiling in Psoriatic Arthritis

Pelosi

Lunardi

Fiore

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Deregulation of miRNAs and the corresponding target gene expression have been shown to be involved in psoriasis pathogenesis [14,15]. miRNAs play a critical role in various autoimmune diseases, including psoriasis [16][17][18]. Recently, the number of miRNAs involved in immune system function and development has increased remarkably, and there has been a wide-ranging discussion of their possible use in therapies for immunological diseases [19].…”

Section: Introductionmentioning

confidence: 99%

Plasma MicroRNA Expression Profiles in Psoriasis

Xiao

Liu

Wang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Psoriasis is an immune-mediated inflammatory chronic skin disease characterized by chronic inflammation in the dermis, parakeratosis, and excessive epidermal growth. MicroRNAs (miRNAs) are key regulators of immune responses. Although differential expression of miRNAs has been reported in certain inflammatory autoimmune diseases, their role in psoriasis has not been fully illuminated. Our aims were to confirm plasma miRNA expression signatures in psoriasis and to examine their potential influence on psoriasis pathogenesis. Methods. A miRNome PCR array was used to analyse the plasma of psoriasis patients and healthy donors. We performed miRNA pathway enrichment and target gene network analyses on psoriasis plasma samples. Results. We found several specific plasma miRNA signatures relevant to psoriasis. The miRNAs targeted pathways associated with psoriasis, such as the VEGF, MAPK, and WNT signaling pathways. Network analysis revealed pivotal deregulated plasma miRNAs and their relevant target genes and pathways regulating psoriasis pathogenesis. Conclusions. This study analysed the expression of plasma miRNAs and their target pathways, elucidating the pathogenesis of psoriasis; these results may be used to design novel therapeutic strategies and to identify diagnostic biomarkers for psoriasis.

show abstract

“…Similarly, patients suffering from AS have shown improvements in pain, functional ability and inflammatory markers such as C reactive protein (CRP) upon anti-TNF-α treatment (Bao et al 2014 ; Inman et al 2008 ; Wang et al 2016 ). In addition, global gene expression studies of AS patients demonstrated that genes involved in Toll-like receptor signaling, TNF signaling, type I interferon signaling and wingless-type MMTV integration site family (Wnt) signaling returned to normal levels following TNF-α inhibitors treatment (Dolcino et al 2017 ). These data strongly suggest beneficial role of anti-TNF-α therapy both in RA and AS patients.…”

Section: Introductionmentioning

confidence: 99%

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients

Ciechomska

Bonek

Merdas

et al. 2018

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

In this study, we analysed the expression level of sera circulating miRNA-5196 in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients before and after tumor necrosis factor (TNF)-α therapy as biomarkers predicting positive treatment outcome. We enrolled 10 RA patients, 13 AS patients, and 12 healthy individuals in the study. The expression of miRNA-5196 was measured by real-time polymerase chain reaction before and after anti-TNF-α therapy. Disease activity of RA patients was assessed using disease activity score 28 (DAS28), whereas ankylosing spondylitis DAS (ASDAS) was used in AS patients. MiRNA-5196 expression was significantly higher in patients with RA and AS before TNF-α therapy than in those following anti-TNF-α therapy and healthy controls. Changes in miRNA-5196 expression positively correlated with delta DAS28 or delta ASDAS, respectively, following TNF-α therapy. In contrast, changes in C-reactive protein (CRP) levels in RA and AS patients did not positively correlate with DAS28 or ASDAS changes. Receiver-operating characteristic analysis showed better diagnostic accuracy of miRNA-5196 expression both in RA (area under curve (AUC) = 0.87, p = 0.055) and AS patients (AUC = 0.90, p = 0.050) compared to CRP levels in RA (AUC = 0.75, p = 0.201) and AS patients (AUC = 0.85, p = 0.086) upon biologic therapy treatment. Finding novel biomarkers, including miRNA-5196 which allow to predict and monitor anti-TNF-α response, would be of clinical value especially during the early phase of RA or AS development.

show abstract

Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy

Cited by 14 publications

References 55 publications

MicroRNA Expression Profiling in Psoriatic Arthritis

MicroRNA Expression Profiling in Psoriatic Arthritis

Plasma MicroRNA Expression Profiles in Psoriasis

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients

Contact Info

Product

Resources

About